Skip to main content
Premium Trial:

Request an Annual Quote

Reprogen Closes on $6.5 Million Private Financing, Appoints CFO

Premium

IRVINE, Calif.--Reprogen, a privately held functional genomics company here with a focus on reproductive medicine, announced the second closing of $1.4 million in a private financing round. The company announced the first closing of this round in February at $5.1 million. New participants included a Munich-based venture capital fund, Life Science Ventures, and Hambrecht and Quist. Reprogen CEO Jeffrey Miller said the financing provides a foundation for Reprogen to continue to enhance its three proprietary technologies. "These platforms enable us to efficiently identify and characterize novel drug targets involved in reproductive diseases," Miller said.

Miller credits Reprogen's new chief financial officer and vice-president of finance and administration, Sharon Tetlow, with bringing high-quality investors to its second closing. Tetlow, formerly of Terrapin Technologies, Synergen, Genentech, and Eli Lilly, brings 12 years' pharmaceutical and biotech experience to Reprogen. She holds an MBA from Stanford University.

Filed under

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.